Table 1.
Patients characteristics. KPS: Karnosky Performance Status. TNL: total number of tumor lesions. SMD: sum of maximum diameter of all measurable lesions in mm.
| Characteristic | % of Patients (Total n = 45) | Characteristic | % of Patients (Total n = 45) |
|---|---|---|---|
| Median Age (years, range) | 67 (41–89) | Median Karnofsky Performance Status (KPS) score (range) | 100 (60–100) |
| Gender | Sidedness | ||
| Female | 36% (16) | Right | 22% (10) |
| Male | 64% (29) | Left | 78% (35) |
| Metastasis | Mutational status in tissue | ||
| Liver only | 24% (11) | BRAF mutation | 13% (6) |
| Liver and others | 67% (30) | RAS mutation | 34% (15) |
| Non-liver only | 9% (4) | RAS/BRAF wild type | 53% (24) |
| Tumor burden | Treatment | ||
| TNL | 4 (1–56) | FOLFOX-bevacizumab | 47% (21) |
| SMD | 122 mm (25–1687) | FOLFOX-panitumumab | 53% (24) |
| Primary Resection | Tumor markers | ||
| Yes | 73% (33) | Carcinoembryonic antigen (CEA) (median ng/mL, range) | 599 (0.62–5580) |
| No | 27% (12) | CA19.9 (median ng/mL, range) | 214 (1–19,032) |